Abstract | BACKGROUND: The usefulness of bronchodilators in coronavirus diseases 2019 (COVID-19) survivors is still uncertain, especially for patients with a concomitant obstructive lung disease. We aimed at verifying the level of bronchodilator reversibility in COVID-19 patients undergoing multidisciplinary pulmonary rehabilitation after the acute phase. METHODS: We enrolled 105 consecutive patients referring to the Pulmonary Rehabilitation Unit of Istituti Clinici Scientifici Maugeri Spa SB, IRCCS of Telese Terme, Benevento, Italy after being discharged from the COVID-19 acute care ward and after recovering from acute COVID-19 pneumonia. All subjects performed a spirometry before and after inhalation of salbutamol 400 μg to determine the bronchodilation response within 48 h of admission to the unit. RESULTS: CONCLUSIONS: This study suggests that a treatment with bronchodilators must always be taken into consideration in post-COVID-19 patients because it can induce a functional improvement that, even if small, can facilitate the breathing of these patients.
|
Authors | Mauro Maniscalco, Pasquale Ambrosino, Salvatore Fuschillo, Silvia Stufano, Alessandro Sanduzzi, Maria Gabriella Matera, Mario Cazzola |
Journal | Respiratory medicine
(Respir Med)
Vol. 182
Pg. 106401
(06 2021)
ISSN: 1532-3064 [Electronic] England |
PMID | 33873099
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Administration, Inhalation
- Aged
- Bronchodilator Agents
(administration & dosage)
- COVID-19
(complications, epidemiology)
- Female
- Forced Expiratory Volume
(drug effects)
- Humans
- Lung
(drug effects, physiopathology)
- Male
- Middle Aged
- Pandemics
- Pulmonary Disease, Chronic Obstructive
(etiology, physiopathology, rehabilitation)
- Respiratory Function Tests
- SARS-CoV-2
|